Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Future CAGR is Anticipated for the Egrifta (Tesamorelin Acetate) Market Over the 2025–2034 Period?

In recent times, the market size of egrifta (tesamorelin acetate) has experienced a XX (CAGR). The market is expected to escalate from $XX million in 2024 to $XX million in 2025, recording a compound annual growth rate (CAGR) of XX%. The growth during the historical period is due to factors such as an increase in understanding about HIV-related issues, a surge in the demand for drug treatments, a rise in the application of antiretroviral therapy, a greater emphasis on life quality, advancements in medical investigations, and heightened public awareness.

The market size for egrifta (tesamorelin acetate) is projected to experience an XX (CAGR) in the ensuing years, escalating to $XX million by 2029 at a compound annual growth rate (CAGR) of XX%. This anticipated expansion during the prediction span is tied to increasing instances of chronic illnesses, expansions in the number of hospitals, growing demand for sophisticated body health screening tools, a higher incidence of metabolic ailments, and heightened consciousness regarding disease management. The prediction period is set to see notable trends such as the mushrooming preference for targeted therapies, assimilation with all-inclusive treatment agendas, escalation in personalized healthcare, amplified patient support initiatives, and a surge in research pursuits.

What Are the Primary Drivers Supporting the Growth of the Egrifta (Tesamorelin Acetate) Market?

The surge in the number of human immunodeficiency virus (HIV) instances is markedly propelling the growth of the egrifta (tesamorelin acetate) market. HIV cases involve situations in which people are infected with HIV, which slowly erodes their immune systems. The escalating number of HIV cases can be partially attributed to a lack of adequate knowledge and education regarding prevention strategies, such as using condoms and undergoing regular check-ups, especially among vulnerable groups. Egrifta, by stimulating the release of the growth hormone, helps to reduce excess deep-seated fat and enhances body composition, ultimately enhancing the overall wellness and life quality for HIV patients. For example, in May 2024, the Minnesota Department of Health, a state health agency in the US, reported 324 fresh HIV diagnoses in 2023, which is a 24% increase from 2022. Therefore, the ascendance of human immunodeficiency virus (HIV) instances is fuelling the expansion of the egrifta (tesamorelin acetate) market.

Explore Comprehensive Insights Into The Global Egrifta (Tesamorelin Acetate) Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

Who Are the Influential Players Fueling Innovation and Growth in the Egrifta (Tesamorelin Acetate) Market?

Major companies operating in the egrifta (tesamorelin acetate) market include Theratechnologies Inc.

What Impact Are Industry Trends Having on the Egrifta (Tesamorelin Acetate) Market’s Future Prospects?

A major trend in the egrifta (tesamorelin acetate) market is the increased focus on creating highly advanced synthetic peptide drugs to improve treatments for HIV-related lipodystrophy. These synthetic peptide drugs are intentionally engineered substances looking to deliver targeted treatment results, either by replicating or improving the functions of natural peptides. For example, Theratechnologies Inc., a Biopharmaceutical firm based in Canada, declared in December 2024 that production of EGRIFTA SV was up and running again after a self-imposed halt at its contract maker’s facility because of observations during an FDA inspection. A freshly produced batch has gone through quality control and awaits the clearance of a prior approval supplement from US Food and Drug Administration (FDA), plus two extra batches are being produced. To satisfy patient needs till mid-January 2025, the company is managing its inventory and coordinating with the FDA to avoid any shortage in supply in 2025. EGRIFTA SV is exclusively available in the US.

Secure Your Global Egrifta (Tesamorelin Acetate) Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

How Are the Key Segments of the Egrifta (Tesamorelin Acetate) Market Impacting Its Expansion and Revenue Streams?

The egrifta (tesamorelin acetate) market covered in this report is segmented –

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

What Regions Are Leading the Growth Trajectory of the Egrifta (Tesamorelin Acetate) Market?

North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Do Experts Define the Scope of the Egrifta (Tesamorelin Acetate) Market?

Egrifta (tesamorelin acetate) is a synthetic peptide that reduces excess abdominal fat in HIV patients with lipodystrophy by stimulating growth hormone release. It acts as a growth hormone-releasing hormone (GHRH) analog to target and decrease visceral fat. By promoting fat breakdown, it improves fat distribution and reduces health risks associated with abdominal fat.

Browse Through More Similar Reports By The Business Research Company:

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Parathyroid Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Follicle Stimulating Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: